Macquarie Group’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Macquarie Group’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-69,667	Closed	-$24K	–	2388
2018 Q2	$24K	Hold	69,667	–	–	﹤0.01%	2052
2018 Q1	$105K	Hold	69,667	–	–	﹤0.01%	1866
2017 Q4	$99K	Hold	69,667	–	–	﹤0.01%	1903
2017 Q3	$160K	Hold	69,667	–	–	﹤0.01%	1813
2017 Q2	$94K	Hold	69,667	–	–	﹤0.01%	1474
2017 Q1	$149K	Hold	69,667	–	–	﹤0.01%	1465
2016 Q4	$307K	Sell	69,667 -80,333	-54%	-$381K	﹤0.01%	1386
2016 Q3	$728K	Hold	150,000	–	–	﹤0.01%	1223
2016 Q2	$495K	Hold	150,000	–	–	﹤0.01%	1277
2016 Q1	$533K	Buy	+150,000	New	+$773K	﹤0.01%	1225

Other funds holding ARLZ

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Macquarie Group's ARLZ Position: Q3 2018 in Review

Macquarie Group sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 69,667 shares — an estimated $24K sold.

Macquarie Group first reported a position in ARLZ in Q1 2016 and held it in 10 quarters. The position peaked at $728K in Q3 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

Macquarie Group reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
Macquarie Group sold 69,667 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $24K.
Macquarie Group first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 10 quarters.
Macquarie Group's Aralez Pharmaceuticals Inc. position peaked at $728K in Q3 2016.
4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Macquarie Group's 13F filing for Q3 2018, filed 15 Nov 2018.